Concord Medical Co., Ltd. (TPEX:6518)
Taiwan · Delayed Price · Currency is TWD 30.70
+0.85 (2.85%)
May 29, 2026, 1:08 PM CST
Concord Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 964.35 | 889.85 | 833.2 | 889.21 | 738.99 | |
Revenue Growth (YoY) | 8.37% | 6.80% | -6.30% | 20.33% | -8.73% |
Cost of Revenue | 830.39 | 780.23 | 731.06 | 780.11 | 670.5 |
Gross Profit | 133.96 | 109.62 | 102.15 | 109.1 | 68.49 |
Selling, General & Admin | 61.16 | 47.79 | 47.23 | 45 | 32.86 |
Operating Expenses | 61.19 | 48.81 | 47.41 | 44.31 | 31.02 |
Operating Income | 72.78 | 60.81 | 54.74 | 64.78 | 37.47 |
Interest Expense | -3.89 | -3.55 | -3.52 | -3.51 | -4.79 |
Interest & Investment Income | 5.21 | 3.99 | 2.87 | 0.9 | 1.03 |
Currency Exchange Gain (Loss) | - | - | - | 0.02 | -0.17 |
Other Non Operating Income (Expenses) | -0.12 | 1.06 | 0.03 | 0.26 | -0.08 |
EBT Excluding Unusual Items | 73.96 | 62.3 | 54.12 | 62.45 | 33.47 |
Gain (Loss) on Sale of Investments | 8.8 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.07 | 0.15 | 0.41 | 1.69 | 9.16 |
Other Unusual Items | - | - | - | 0.09 | 0.17 |
Pretax Income | 82.83 | 62.45 | 54.53 | 64.22 | 42.79 |
Income Tax Expense | 14.9 | 12.88 | 11.78 | 13.58 | 8.39 |
Earnings From Continuing Operations | 67.93 | 49.57 | 42.74 | 50.64 | 34.4 |
Minority Interest in Earnings | -0.57 | - | - | 0.02 | - |
Net Income | 67.36 | 49.57 | 42.74 | 50.66 | 34.4 |
Net Income to Common | 67.36 | 49.57 | 42.74 | 50.66 | 34.4 |
Net Income Growth | 35.90% | 15.97% | -15.62% | 47.27% | 73.96% |
Shares Outstanding (Basic) | 33 | 33 | 33 | 33 | 25 |
Shares Outstanding (Diluted) | 34 | 33 | 33 | 33 | 25 |
Shares Change (YoY) | 0.12% | 0.07% | 0.17% | 33.03% | 0.22% |
EPS (Basic) | 2.02 | 1.49 | 1.28 | 1.52 | 1.37 |
EPS (Diluted) | 2.01 | 1.48 | 1.28 | 1.52 | 1.37 |
EPS Growth | 35.81% | 15.63% | -15.77% | 10.93% | 73.42% |
Free Cash Flow | 123.42 | 74.12 | 25.05 | 117.1 | 115.63 |
Free Cash Flow Per Share | 3.68 | 2.21 | 0.75 | 3.51 | 4.61 |
Dividend Per Share | 1.500 | 1.100 | 1.000 | 1.000 | 0.500 |
Dividend Growth | 36.36% | 10.00% | - | 100.00% | 25.00% |
Gross Margin | 13.89% | 12.32% | 12.26% | 12.27% | 9.27% |
Operating Margin | 7.55% | 6.83% | 6.57% | 7.29% | 5.07% |
Profit Margin | 6.98% | 5.57% | 5.13% | 5.70% | 4.66% |
Free Cash Flow Margin | 12.80% | 8.33% | 3.01% | 13.17% | 15.65% |
EBITDA | 128.96 | 119.78 | 131.35 | 138.83 | 111.84 |
EBITDA Margin | 13.37% | 13.46% | 15.76% | 15.61% | 15.13% |
D&A For EBITDA | 56.18 | 58.97 | 76.61 | 74.05 | 74.37 |
EBIT | 72.78 | 60.81 | 54.74 | 64.78 | 37.47 |
EBIT Margin | 7.55% | 6.83% | 6.57% | 7.29% | 5.07% |
Effective Tax Rate | 17.99% | 20.62% | 21.61% | 21.15% | 19.61% |